Novel Dose Escalation to Predict Treatment With Hydroxyurea

NCT02042222 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Hydroxyurea

Sponsor

Baylor College of Medicine

Collaborators

[object Object]